BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/3/2026 1:23:53 AM | Browse: 3 | Download: 2
 |
Received |
|
2026-01-30 00:28 |
|
Peer-Review Started |
|
2026-01-30 00:31 |
|
First Decision by Editorial Office Director |
|
2026-02-12 08:24 |
|
Return for Revision |
|
2026-02-12 08:24 |
|
Revised |
|
2026-03-13 01:37 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-04-15 02:37 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-04-15 03:59 |
|
Articles in Press |
|
2026-04-15 03:59 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-07-23 03:40 |
|
Publish the Manuscript Online |
|
2026-08-03 01:23 |
| ISSN |
2219-2808 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Pediatrics |
| Manuscript Type |
Retrospective Study |
| Article Title |
Sirolimus for the treatment of vascular tumors and malformations in children: A 10-year single-institution retrospective study
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Nattaporn Thongngam, Lalita Sathitsamitphong, Wipawee Morakote, Supapitch Chanthong, Supawadee Maneekesorn, Rungrote Natesirinilkul, Pimlak Charoenkwan and Chane Choed-Amphai |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Chane Choed-Amphai, Assistant Professor, MD, PhD, Department of Pediatrics, Faculty of Medicine, Chiang Mai University, No. 110 Intawarorot Road, Sriphum, Muang, Chiang Mai 50200, Thailand. chane.c@cmu.ac.th |
| Key Words |
Sirolimus; Vascular anomalies; Vascular malformations; Vascular tumors; Children |
| Core Tip |
Sirolimus is increasingly used as targeted therapy for pediatric vascular anomalies, yet real-world clinical data remain limited. In this retrospective study of children with vascular tumors and malformations, sirolimus demonstrated a high response rate and an acceptable safety profile across diverse disease subtypes. Rapid resolution of Kasabach-Merritt phenomenon was observed in patients with kaposiform hemangioendothelioma receiving combination therapy. However, disease progression occurred after treatment discontinuation, highlighting the need for careful post-therapy monitoring. These findings support sirolimus as an effective treatment option in refractory or unresectable pediatric vascular anomalies and emphasize the importance of optimizing treatment duration and follow-up strategies. |
| Publish Date |
2026-08-03 01:23 |
| Citation |
Thongngam N, Sathitsamitphong L, Morakote W, Chanthong S, Maneekesorn S, Natesirinilkul R, Charoenkwan P, Choed-Amphai C. Sirolimus for the treatment of vascular tumors and malformations in children: A 10-year single-institution retrospective study. World J Clin Pediatr 2026; 15(3): 119506
|
| URL |
https://www.wjgnet.com/2219-2808/full/v15/i3/119506.htm |
| DOI |
https://doi.org/10.5409/wjcp.119506 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
